Berman Brian D, Qeadan Fares, Henderson Amanda D, Harrison Andrew R, Defazio Giovanni, Hallett Mark, Kilic-Berkmen Gamze, Wright Laura, Pentecost Samantha, Reyes Paul, Tingin Anna, Jankovic Joseph, Boyd Jane, Hudgins Charlene, Hieshetter Janet, Perlmutter Joel S, Jinnah Hyder A, Pirio Richardson Sarah
Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Department of Public Health Sciences, Loyola University Chicago, Chicago, IL 60153, USA.
Toxins (Basel). 2025 Sep 10;17(9):455. doi: 10.3390/toxins17090455.
Blepharospasm (BSP) is characterized by excessive orbicularis oculi muscle activity leading to abnormal blinking and involuntary eyelid closure. Botulinum neurotoxin (BoNT) injections are the main treatment for BSP, but they only partially and transiently relieve symptoms, leading to a waxing and waning therapeutic response. A patient-centered outcome (PCO) tool that measures BSP symptoms in a simple and efficient way could inform the development of better treatments. Using a stepwise modified Delphi approach, potential PCO items were first identified using the Dystonia Coalition Database with data from over 200 individuals with BSP who had provided responses to existing clinical assessment scales. These items were then analyzed for contribution to overall severity using a Random Forests approach, and redundant items were merged and revised in a series of iterative meetings with a specialist panel along with input from patient advocacy group representatives and focus groups. An online survey was conducted with 330 individuals with BSP to validate and verify the items' relevance. Finally, the specialist panel provided content validity ratio, which was repeated until it showed good agreement for relevance and clarity of all items. In the end, an easy-to-use PCO tool designed for smartphones and tablets containing 17 items covering three symptom domains (motor, disability, and psychosocial/quality of life) was created. This novel PCO tool for BSP may be used to characterize the cyclical response that an individual patient experiences from BoNT treatments and provide a vital tool for future investigations of longer-acting BoNT preparations or adjunctive therapies.
眼睑痉挛(BSP)的特征是眼轮匝肌活动过度,导致异常眨眼和不自主眼睑闭合。肉毒杆菌神经毒素(BoNT)注射是BSP的主要治疗方法,但它们只能部分且短暂地缓解症状,导致治疗反应时好时坏。一种以患者为中心的结局(PCO)工具,能够以简单有效的方式测量BSP症状,可为更好治疗方法的开发提供参考。采用逐步改良的德尔菲法,首先利用肌张力障碍联盟数据库,从200多名已对现有临床评估量表做出回应的BSP患者的数据中识别潜在的PCO项目。然后使用随机森林方法分析这些项目对总体严重程度的贡献,并在与专家小组的一系列迭代会议中,结合患者倡导团体代表和焦点小组的意见,对冗余项目进行合并和修订。对330名BSP患者进行了在线调查,以验证这些项目的相关性。最后,专家小组提供了内容效度比,并反复进行直至所有项目在相关性和清晰度上显示出良好的一致性。最终,创建了一种专为智能手机和平板电脑设计的易于使用的PCO工具,其中包含17个项目,涵盖三个症状领域(运动、残疾和心理社会/生活质量)。这种用于BSP的新型PCO工具可用于描述个体患者从BoNT治疗中经历的周期性反应,并为未来长效BoNT制剂或辅助治疗的研究提供重要工具。